1 cancer treatment stock which is now an opportunity to buy

There is good news in the fight against cancer. While many people around the world are still affected by this disease, innovative companies are advancing in the diagnosis and treatment of cancer. Many of these companies offer great opportunities for long-term investors.

Keith Speights, our author of Motley Fool, asked for the cancer treatment actions that he now considered as an opportunity to purchase. The reasons why he Illumina (WKN: 927079), we clarify here.

Three-sided attack on cancer

Illumina may not have the idea of ​​treating cancer first. But the leader in gene sequencing is a major player in the fight against cancer. And in three ways.

First, Illumina helps scientists explore the root causes of various cancers. They can therefore develop effective drugs. Second, the company's products are used in diagnostics when processing with high precision medical devices. This is especially the case with immunotherapy. Third, Illuminas gene sequencing systems are used in the study of fluid biopsies to detect cancer at a very early stage.

Do not be fooled by Illumina's slowing revenue and earnings growth in the first quarter. The turnover is expected to pick up steam in the second half of 2019, as large genome-related projects intensify and customers spend more before the end of the year.

The long-term prospects for Illumina are even more important. This one is really good. Genetic examinations play an increasingly important role in understanding rare and undiagnosed diseases. Consumer health surveys, as proposed by Ancestry.com and 23andMe, are becoming increasingly popular as genetic factors affecting health become known. Both companies are also Illumina customers. The explosion of personalized medicine and the huge potential for liquid biopsies could be an even more important catalyst for Illumina in the future.

Our best stock for the year 2019

There is a company whose name is currently very common among The Motley Fool analysts. This is the best investment for us in 2019. Motley Fool analysts give a strong buy signal! You could also benefit … First, you must know everything about this unique company. Therefore, we have put together a free special report that presents this company in detail. Click here to download this report for free.


Keith Speights holds shares in Illumina. The Motley Fool owns and recommends Illumina shares.

This article was written by Keith Speights in English and the 23.05.2019 on fool.com published. It has been translated so that our German readers can participate in the discussion.